A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age
Phase of Trial: Phase I/II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Multivalent group B streptococcus vaccine-Pfizer (Primary)
- Indications Streptococcal infections
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 28 Jun 2017 Planned End Date changed from 15 May 2018 to 13 Jun 2018.
- 28 Jun 2017 Planned primary completion date changed from 15 May 2018 to 13 Jun 2018.
- 28 Jun 2017 Status changed from not yet recruiting to recruiting.